

Mirati Therapeutics, Inc.  
Form 8-K  
April 10, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 5, 2018**

**MIRATI THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State of**  
  
**incorporation)**

**001-35921**  
**(Commission**  
  
**File No.)**  
**9393 Towne Centre Drive, Suite 200**

**46-2693615**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: Mirati Therapeutics, Inc. - Form 8-K

**San Diego, California 92121**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (858) 332-3410**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement**

On April 5, 2018, the Company entered into a Second Amendment to Lease Agreement (the Amendment ) with ARE-SD Region No. 20 (the Landlord ) to amend the Lease Agreement, dated June 24, 2014, and the First Amendment to Lease dated March 23, 2017 (the Amended Lease ) between the Company and Landlord. The Amendment extends the term of the Amended Lease for one year through January 31, 2020. All other material terms and covenants from the Amended Lease remain unchanged.

A copy of the Amendment is filed as Exhibit 10.1 to this report and the description of the terms of the Amendment is qualified in its entirety by reference to such exhibit.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

**Exhibit**

<b>No.</b>	<b>Description</b>
10.1	<u>Second Amendment to Lease to 9393 Towne Centre Drive, dated April 5, 2018.</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MIRATI THERAPEUTICS, INC.**

Date: April 10, 2018

By: /s/ Jamie A. Donadio  
Jamie A. Donadio  
Senior Vice President and Chief Financial Officer